

## ABSTRACT

TP53 is a tumor suppressor gene whose product is involved in cellular growth inhibition, apoptosis and senescence. Two new classes of proteins recently discovered, p63 and p73 proteins, share with p53 a high structural homology and overlapping yet specific functions.

p63 and p73 can be expressed as TA forms that have the Transcriptional Activation Domain, behave as p53-like proteins and show variability at the C-terminus due to alternative splicing. Indeed p63 and p73 can be also expressed from an alternative promoter or by N-terminal alternative splicing and the products are  $\Delta Np73$  or  $\Delta TAp73$  forms that are truncated at the N-terminus and act as dominant negative proteins of the other p53 family members.

Although p53 family proteins share the main functional domains and activate the transcription of a subset of common genes, unlike p53, p73 and p63 do not have clear features of tumor suppressors. Actually their activity is more complex and still not well defined. The entire p73 network of proteins, in fact, is involved in neuronal differentiation, in the apoptotic response to damaging agents (cisplatin, IR, doxorubicin) and in tumorigenesis.

TP73 gene is transcriptionally regulated by E2F1, in the G1/S transition and in the DNA damage or oncogenes activated apoptotic response. The p73 protein functions are modulated by post-translational modifications and protein-protein interactions in different physiopathological cellular contexts.

The aim of this PhD thesis has been the characterization of post-translational modifications that regulate p73 transcriptional functions upon DNA damage and in physiological contexts.

A new post-translational modification induced by Doxorubicin treatment has been identified during the first part of my PhD experience. In fact, upon Doxo treatment p73 protein is induced and acetylated by p300 acetyltransferase. The region involved in acetylation has been found using deletion and point mutation mutants: it maps between the DNA Binding Domain and the Oligomerization Domain and the Lysines involved are K321, K327 and K331. The not acetylatable p73RRR mutant binds DNA and activates the transcription of p21 target gene but is unable to activate DNA damage apoptotic response. Thus DNA damage-induced p300-mediated acetylation of p73 seems to be important to recruit p73 transcription factor directly on apoptotic genes (p53AIP1) rather than on growth arrest genes (p21). Moreover p73 acetylation is dependent on tyrosine-kinase c-Abl activity, as well involved in pro-apoptotic p73 functions induced by damaging agents (IR and cisplatin).

The study of p73 post-translational modifications continued with the attempt to assess how p73 activity is regulated during the cell cycle.

p73 $\alpha$  and p73 $\beta$  are phosphorylated in normal mitotic cells or in spindle drug arrested mitotic cells and the p34<sup>cdc2</sup>/cyclin B1 complex has been identified, by *in vitro* kinase assays, as responsible for this phosphorylation. Moreover p73 interacts with and is phosphorylated by the p34<sup>cdc2</sup>/cyclin B1 complex in the amino-terminal region on the Threonine 86 residue. Thr86 phosphorylation reduces p73 DNA binding and transcriptional activities during mitosis and delocalizes the protein from condensed mitotic chromatin. In late telophase p73 lacks phosphorylation and is able to localize again with decondensed chromosome likely resuming its transcriptional activity. Interfering with p73 expression and function, by specific siRNAs or by the use of the dominant negative p73DD mutant, results in an altered mitotic progression, formation of mitotic abnormalities and increase in binucleated cells. Thus p73 seems to be involved in M/G1 transition and in the correct cell division.

Taken together these results suggest that p73 activating transcriptional functions can be specifically modulated by post-translational modifications in different physiopathological contexts.

## ABSTRACT

## INTRODUCTION

### CHAPTER 1.

p73 and the p53 family: a complex network of proteins	
The TP53 tumor suppressor gene: a question of life or death	1
The TP73 gene locus: a variety of isoforms	1
<i>Structural domains of p53 family members</i>	1
<i>p73 isoforms generated by alternative splicing</i>	5
<i>p73 isoforms generated by the use of alternative promoters</i>	6
Regulation of p73 activity	6
<i>Regulation of p73 expression by different promoters activity</i>	6
<i>Interaction of p73 with regulatory protein</i>	9
<u><i>Mutual interactions with the other p53 members</i></u>	9
<u><i>MDM2</i></u>	11
<u><i>YAP</i></u>	12
<u><i>Viral oncoproteins</i></u>	12
p73 subcellular localization	13
p73 involvement in development, differentiation and senescence	15
p73 and malignancy: tumor suppressor or not?	18
<i>Loss of heterozygosity (LOH),</i>	
<i>imprinting and promoter silencing</i>	18
<i>Mutations of p73 in primary cancer</i>	20
<i>Overexpression of wild-type p73</i>	20
<i>Upregulation of p73 by oncogenes</i>	21
<i>Expression of <math>\Delta</math>Np73 and <math>\Delta</math>TAp73 isoforms</i>	22
<i>Inhibition of p73 by p53 mutants</i>	22
<i>p53 family network and chemoresistance</i>	23
Evolution of the p53 family	25

### CHAPTER 2.

p73 functions are modulated by post-translational modifications	
Transcriptional activity of p73	29
p73 and the DNA damage induced response	30
<i>Phosphorylation</i>	32
<i>Modification by Pin1</i>	33
<i>Sumolation</i>	34
p73 regulation during the cell cycle	34

## RESULTS

p73 acetylation upon DNA damage	35
p73 $\alpha$ accumulates and is acetylated by p300 upon DNA damage	37

Lysines at position 321,327,331 of p73 are the major acetylation determinants	40
Nonacetylatable p73 $\alpha$ activates transcription and binds DNA but is deficient in growth suppression and induction of apoptosis	42
Acetylation activates the apoptotic functions of p73	42
c-abl is required for Doxorubicin-induced p300-dependent acetylation of p73 $\alpha$	48
<b>Modulation by phosphorylation of p73 function in mitosis and M/G1 transition</b>	<b>53</b>
p73 $\alpha$ and $\beta$ are phosphorylated during mitosis	53
p73 is phosphorylated by the p34cdc2-cyclin B complex <i>in vivo</i> and <i>in vitro</i>	56
p34cdc2-cyclin B complex binds p73 in mitosis	58
p34cdc2-cyclin B-mediated phosphorylation interferes with p73 functions	60
Hypophosphorylated p73 proteins reassociate with chromatin in telophase	64
Abrogation of p73 function perturbs mitotic progression and exit	64
The kip2p57 cki is a p73 target during the exit from mitosis	68
<b>DISCUSSION</b>	<b>73</b>
<b>EXPERIMENTAL PROCEDURES</b>	
Cell culture and Transfections	77
Antibodies and Reagents	77
Immunoblotting, Immunoprecipitation and Kinase Assays	78
RT-PCR	79
EMSA experiments	79
Binding to biotinylated oligonucleotides	80
Cell Death Assays	80
BrdU Staining	80
Cytological preparation and Microscopies	81
Microinjection	81
Chromatin Immunoprecipitation Assay	81
<b>REFERENCES</b>	<b>83</b>
Short Candidate CV	105
List of Candidate Publications	106
Copy of relevant Candidate Publications	107

## **ACKNOWLEDGMENTS**

I wish to express my deep and sincere gratitude to P Lavia, V Sartorelli, PL Puri, and E Cundari for having provided invaluable discussion, helpful suggestions and support throughout the genesis of the thesis.

# **INTRODUCTION**

